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Background: The purpose of the present study was to examine the relationship between 
cognitive impairment and the performance of handwritten scripts presented as “letter-writing” 
to a close relative by patients with dementia Lewy bodies (DLB), as fluctuations of the symp-
toms phase, and in a matched group of patients with Alzheimer’s disease (AD). The degree of 
writing disability and personal, spatial, and temporal orientation was compared in these two 
groups. 
Design and methods: Fourteen simple questions, designed in a form that could be utilized 
by any general practitioner in order to document the level of cognitive functioning of each 
patient, were presented to 30 AD patients and 26 DLB patients. The initial cognition test was 
designated PQ1. The patients were examined on tests of letter-writing ability. Directly after 
the letter-writing, the list of 14 questions presented in PQ1 was presented again in a repeated 
procedure that was designated PQ2. The difference between these two measures (PQ1 – PQ2) 
was designated D∆. This test of letter-writing ability and cognitive performance was admin-
istered over 19 days.
Results: Several markedly strong relationships between dysgraphia and several measures of 
cognitive performance in AD patients and DLB patients were observed, but the deterioration 
of performance from PQ1 to PQ2 over all test days were markedly significant in AD patients 
and not significant in DLB patients. It is possible that in graphic expression even by patients 
diagnosed with moderate to relatively severe AD and DLB there remains some residual capacity 
for understanding and intention that may be expressed. Furthermore, the deterioration in perfor-
mance and the differences noted in AD and DLB patients may be due to the different speed at 
which the process of the protein degradation occurs for functional modification of synapses.
Conclusion: Our method can be used as part of neuropsychological tests to differentiate the 
diagnosis between AD and DLB.
Keywords: cognition, deficits, correlation, deterioration
Introduction
In Western industrial nations, Alzheimer’s disease (AD) represents the most common 
form of dementia,1,2 at approximately 80%,3 occupying fourth place among the causes 
of death (after heart disease and circulatory disorders, cancer, and cerebral hemor-
rhage). Dementia with Lewy bodies (DLB) is the second most common cause of 
degenerative dementia after AD.
Worldwide there are currently 25 to 35 million individuals with these illnesses, 
with five to seven million new cases diagnosed each year, or one new case every 7 
seconds.4,5 According to the World Health Organization it has been estimated that by the 
year 2050 the number of people presenting with dementia will be 115.4 million.6 
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The pathology of dementia is associated with memory 
loss, loss of orientation, inability to focus attention, and 
loss of speech. In addition, we notice cognitive fluctuations, 
defined as spontaneous alterations in cognition, attention, 
and arousal. Fluctuating confusion, accompanied by dis-
turbances of consciousness, is an important clinical symp-
tom, with a frequency of 80%–90% in DLB7,8 and 20% in 
Alzheimer’s disease.9 In fact, in these patients, cognitive 
fluctuations and periods of behavioral confusion, inatten-
tion, and alternating episodes of lucidity and capable task 
performance have been described.10 McKeith identified the 
“marked amplitude between best and worst performance” 
as a distinguishing feature of the fluctuations in cognition 
and consciousness in DLB, contrasting this with “minor 
day-to-day variations” that can occur in dementia of any 
cause.11 The term cognitive fluctuation remains elusive 
despite several attempts to identify, quantify, and assess 
the phenomenon.12
This fact raises an important question: do the fluctua-
tions occurring in AD patients have a particular quality and 
specific characteristics different from fluctuations that occur 
in DLB dementia?
In addition, many authors have observed in patients 
with AD dementia, a progressive disorganization and 
degeneration of the various components of handwriting, the 
diversity and the accuracy of words used, organization,13 
punctuation,14 the production of grammatically incorrect 
sentences, the length of the sentences, the morphology of 
the letters,15 the amount of written information,16 spelling,17 
and graphic and spatial layout of letters and their arrange-
ment in texts.18
We are not aware of research regarding the degeneration 
of handwriting in DLB patients. The purpose of the present 
study was to examine the relationship between cognitive 
impairment and the performance of handwritten scripts pre-
sented as “letter-writing” to a close relative by AD patients, 
as fluctuations of the symptoms phase, and in a matched 
group of DLB patients.
Also, it is possible that in graphic expression even by 
patients diagnosed with moderate to relatively severe AD 
and DLB there remains some residual capacity for under-
standing and intention that may be expressed. Concurrently, 
the relationship between measures of functioning, Mini-
Mental State Examination (MMSE), and number of years 
elapsed since first indication of disorder with dysgraphia 
and assessments of cognitive performance was assessed 
(or debut).
Materials and methods
Fifty-six patients (from the region of Lazio, Italy) were 
selected to participate in the study: 30 patients presenting 
AD and 26 patients presenting DLB. Patients were diagnosed 
according to the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer’s 
Disease and Related Disorders Association19 and the Diag-
nostic and Statistical Manual of Mental Disorders, 4th 
edition reference.
In addition, a group of 30 younger, less impaired AD 
patients (ADli) was included. Patients were excluded if they 
presented a history of known or suspected cerebrovascular 
disease, focal neurological signs or brain imaging evidence 
for alcohol misuse, head trauma, significant psychiatric 
history preceding the current diagnosis, or any other major 
physical illness. All of these diagnoses were confirmed and 
verified by neurologists in the Department of Neurology at the 
hospital (Gemelli University Polyclinic – service neuropsy-
chology, Roma and the Alzheimer Evaluation Unit ASLRMF 
and Alzheimer Evaluation Unit ASLRMD); 26 patients were 
confirmed by the Department of Neurology and Psychiatry, 
Sapienza Hospital, Rome, Italy, in the Lazio region. Only 
subjects with the clinical follow-up and complete diagnostic 
agreement by the three neurologists were included.
A considerable amount of time (regular meetings 
every second day for 3 months) was invested in each of 
the patients in order to promote a relationship of trust and 
understanding, as well as to reduce stress factors20 that 
may affect patients’ mood and attentiveness, or, more 
seriously, induce behaviors that suggest hallucinations or 
auditory illusions, paranoid delirium, difficulty in recog-
nizing persons, or loss of cognition of time and place. All 
the procedures were adopted according to discussions and 
meetings with nearest relatives and caregivers in order to 
obtain the consent of the patients as well as those of relatives 
and caregivers (caregivers could be legal representatives) 
according to the legal practices.
Alzheimer’s disease
For the sixty patients constituting the AD group and ADli, 
the diagnosis was based on normal or nonspecific electro-
encephalography and lateral, occipital brain atrophy on 
magnetic resonance imaging or computed tomography brain 
scan, with documented progression after serial observations, 
and on cognitive test procedures and routine blood assays 
aimed at excluding the presence of other medical conditions 
associated with other types of dementia.
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Dementia with lewy bodies
Twenty-six DLB patients were included in the study. 
Diagnosis was confirmed using the international  consensus 
guidelines for DLB, revised in 2005.21 All patients 
presented with dementia at the time of their initial evalu-
ation, which usually preceded the onset of motor signs of 
disorder by 1–2 years. Some patients exhibited cognitive 
impairment concomitant with mild extrapyramidal signs, 
which, however, never reached the criteria levels for the 
diagnosis of idiopathic Parkinson’s disease, and showed 
no evidence of focal brain lesions on magnetic resonance 
imaging.
Exclusion criteria were presence of secondary, revers-
ible causes of dementia that were untreated; concomitant 
neurological or psychiatric illness, substance use and abuse; 
and history of significant head trauma. 
Mini-Mental state examination
MMSE presents a brief 30-point questionnaire to screen 
for cognitive impairment and dementia.22 It estimates the 
severity of disorder and follows the course over time of 
cognitive changes in an individual, thereby allowing effective 
monitoring of an individual’s response to treatment.
Unified Parkinson’s Disease Rating Scale
The Unified Parkinson’s Disease Rating Scale is a rating 
scale used to follow the longitudinal course of Parkinson’s 
disease.23 It is the most commonly used scale in the clinical 
study of Parkinson’s disease and of DLB.
Clinician assessment of fluctuation 
(CAF)
CAF is a short scale consisting of a series of screening 
questions, regarding fluctuating confusion and impaired 
consciousness during the month prior to the assessment. 
The frequency and duration of episodes of fluctuating con-
fusion are both rated on a scale of 0–12 (0 representing no 
fluctuating confusion, 12 representing severe fluctuating 
confusion).24 
Cognitive performance assessment
Testing material
A writing pad was used for writing text or drawing figures. 
Preferably the tablet was vergatina type (flimsy typing paper, 
tissue type, or absorbent in order to avoid false interpretations 
of the writings). A ballpoint pen was used throughout. 
The patients were invited to sit in a comfortable position.
Procedure
In order to test the cognitive performance of AD patients 
and DLB patients as well as test their spatial and time 
 orientation and residual capacity, a standard collection of 14 
simple questions were presented to the patients (Table 1). 
The authors have designed and presented these questions 
in a form that could be utilized by any general practitioner 
in order to document the level of cognitive functioning of 
each patient. For each correct answer, one point was attrib-
uted in proportion to the difficulty of the question.25 The 
sum of each test session was represented by PQ; the initial 
session result was designated PQ1. Following this, each 
patient was then invited to write a letter to a close relative. 
On consecutive days of testing, patients were invited to write 
to either the same relative or another one. The letter-writing 
task was interrupted when it seemed that the text produced by 
the patient was substantially (pathologically) confused (when 
the phrase offered no conceptual association with accompa-
nying text although in the presence of otherwise “correct” 
syntax) and when it had a sudden lack of readability, dis-
jointedness, and incompleteness in meaning, with intrusions, 
semantic substitutions, alterations in the spatial organization 
of handwriting, illegible words, incidence of paraphrases, 
incapacity to form complete sentences, graphemic substitu-
tions (a grapheme is the smallest semantically distinguishing 
unit in a written language), omissions, and additions. After 
this, using a chronometer, the number of minutes that had 
been reached for each single patient was registered and com-
plete sentences were counted (sentences/minutes = XF). The 
whole procedure involving the letter-writing graphia task was 
interrupted after 20 minutes (see Figure 1).
Table 1 example scoring list of 14 questions presented to a 
hypothetical AD patient in PQ1 phase and PQ2 phase. These are 
routine questions which a doctor can ask to the patient
Questions Score
 1. What is your name? 0–3
 2. When were you born? 0–2
 3. Where were you born? 0–2
 4. Which city do you live? 0–1
 5. What is your address? 0–1
 6. Who are you living with? 0–1
 7. have you got children? 0–1
 8. What are their names? 0–2
 9. Why are you here? 0–1
 10. have you pain? 0–1
 11. Where have you pain? 0–1
 12. how did you get here? 0–1
 13. How much time did you take to get here? 0–1
 14. What day is today? 0–2
Abbreviations: AD, Alzheimer’s disease; PQ, cognition test.
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Figure 1 The performance of AD patient X and DLB patient X during PQ1, followed by the letter-writing test, followed by PQ2.
Note: The quality of handwriting, coherence, and comprehension is taken into account before deciding to terminate the writing session.
Abbreviations: AD, Alzheimer’s disease; DlB, dementia lewy bodies; PQ1, initial cognition test; PQ2, repeated cognition test.
Directly after letter-writing
The list of 14 questions presented in PQ1 was presented 
again in a repeated procedure that was designated PQ2. 
The difference between these two measures (PQ1 – PQ2) 
was designated D∆. These procedures for testing: 14-item 
test, graphia test, 14-item test were presented in an identi-
cal manner every second day over 10 days (days 1, 3, 5, 7, 
9, 11, 13, 15, 17, and 19) at the same hour of day on test 
days in order to hold constant testing procedures over daily 
curriculum and any clinical interventions that the patients 
may be subject to.
statistical analysis
The results consisting of PQ1 and PQ2 scores, XF, and D∆ 
were calculated as means and standard deviations of the AD 
patient group and the DLB patients over consecutive days of 
testing. Pearson’s correlation coefficient was used to assess 
the relationship between XF and PQ1 and XF and D∆ for 
both AD patients and DLB patients for each of the test days. 
Student’s t-tests were used to test for pairwise differences 
for each of the parameters. 
Results
The clinical characteristics of the participants in the study 
are presented in Table 2.
AD, ADli, and DlB patients: cognitive 
performance over PQ1 and PQ2
The cognitive performance of the AD patients and DLB 
patients deteriorated from PQ1 to PQ2 (Table 3), with t-values 
reaching significance levels over all 10 days of testing.
The cognitive performance of ADli patients deteriorated 
from PQ1 to PQ2 (Table 4).
Comparison of AD, ADli with DlB 
patients: correlation coefficients PQ1 
versus XF and XF versus D∆
The correlation coefficients of both the PQ1 performance 
and XF relationship and the XF and D∆ relationship were 
all positive and highly significant in AD patients while they 
were positive in ADli patients. In DLB patients the correla-
tion coefficient of the PQ1 performance and XF relationship 
was positive while the correlation analysis of the XF and D∆ 
relationship was negative (Tables 3 and 4).
Correlation analyses between functional 
measures
Product moment correlations between the functional esti-
mations of MMSE, debut (years), PQ1, D∆, and PQ2 were 
Table 2 Clinical, demographic, and neuropsychological data of 
the study groups
AD DLB AD younger
sex (M/F) 40% M 60% F 46.15% M 53.85% F 35% M 55% F
Mean age (years) 83.06±6.15 78±6.4 77.4±5.8
educational (years) 11.0±3.6 10.3±2.3 11.3±2.6
Debut (years) 4.43±1.19 3.3±0.6 3.4±1.23
MMse 13.75±1.96 14.3±1.5 20.56±1.6
UPDRS 0 61.87±2.5 0
CAF 2.5 6.7 0
Notes: Values are reported as mean ± standard deviation; Debut is defined as 
number of years elapsed since first indication of disorder.
Abbreviations: AD, Alzheimer’s disease; CAF, clinician assessment of fluctuation; 
DlB, dementia lewy bodies; F, female; M, male; MMse, Mini-Mental state examination; 
UPDRS, Unified Parkinson’s Disease Rating Scale.
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carried out on the data obtained from the 30 AD patients and 
26 DLB patients. It was observed that 1) MMSE is correlated 
significantly with PQ1, XF, and PQ2, 2) MMSE is correlated 
significantly with D∆ in AD patient while the correlation is 
negative in DLB patients, and 3) debut (years) does not cor-
related with PQ1, XF, PQ2, and D∆ in AD patient while the 
correlations are not significant in DLB patients (Table 5).
Comparison AD patients 
with DlB patients
The cognitive impairment that occurs after the write perfor-
mance in AD patients is clearly shown in Figure 2. The blue 
plot shows the levels of cognitive impairment that occurred 
before the writing performance in AD and DLB patients (over 
10 days of testing) day after day. The red plot emphasizes the 
cognitive level after the writing test (Figures 2 and 3).
Concurrently, the extent of cognitive performance 
deterioration; D∆ from the 1st to the 2nd test was found to 
be markedly advanced in AD patients in comparison with 
the DLB patients (Figure 4). 
The extent of dysgraphia by the DLB patients was found 
to be quite advanced in comparison with the AD patients 
(Figure 5).
Discussion
This study shows the distinctive features of the cognitive 
impairment in relation to dysgraphia during the cognitive 
daily fluctuations in DLB patients and in AD patients.
The cognitive impairment, spontaneous alterations in 
attention, and incoherent speech, alternating with episodes 
of lucidity and capable task performance are a recognized 
feature of dementia, especially in DLB, but they are present 
also in AD.
We examined the relationships between initial cognitive 
performance (PQ1), the deterioration in cognitive perfor-
mance following a letter-writing task (PQ1 – PQ2 = D∆) 
and dysgraphia (XF) in a group of AD patients present-
ing a moderate to relatively severe stage of disorder, and 
comparisons with a group of DLB patients and with ADli 
patients. The results may be summarized as follows: 1) the 
relationships between initial cognitive performance (PQ1) 
and extent and dysgraphia over both AD and DLB patients 
and test days were markedly strong; 2) but the deterioration 
of performance from PQ1 to PQ2 over all test days was mark-
edly significant in AD patients, and it was not significant in 
DLB patients; 3) the relationships between dysgraphia and 
cognitive deterioration (D∆) were also markedly strong in 
AD patients, and they were not significant in DLB patients; T
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Table 4 Younger, less impaired AD patient student’s t-test values between PQ1 and PQ2 scores (means ± SD) and Pearson product 
moment correlational analyses between 1) PQ1 and XF, 2) XF and D∆ over 10 days of testing (days 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19)
Test days PQ1 AD PQ2 AD t-values AD R (1) AD R (2) AD
1 16.0±2.1 10.3±1.8 10.92 0.578 0.533*
3 15.6±2.5 9.7±2.0 10.29 0.656* 0.536
5 15.3±2.7 9.7±1.9 10.28 0.616* 0.578*
7 15.3±2.7 10.0±1.8 8.84 0.689 0.696*
9 15.4±2.6 10.0±1.9 8.84 0.698* 0.663
11 15.3±2.7 9.5±1.7 9.93 0.602* 0.536
13 16.9±2.5 9.4±1.5 14.81 0.657* 0.576*
15 15.3±2.7 10.0±1.9 8.84 0.603• 0.553
17 15.5±2.7 10.0±1.8 8.84 0.651 0.635
19 15.4±2.7 9.8±1.9 9.45 0.695* 0.586
Notes: *t-tests (df=58); P 0.0001; •P0.005; P0.002; P0.001.
Abbreviations: AD, Alzheimer’s disease; D∆, difference between the measures of PQ1 and PQ2; PQ1, initial cognition test; PQ2, repeated cognition test; SD, standard 
deviation; XF, number of complete sentences/minutes reached for each patient.
4) MMSE correlated significantly with PQ1, PQ2, and with 
XF in both groups of patients; furthermore, number of years 
elapsed since first diagnosis of disorder does not affect the 
XF (or expression of dysgraphia), PQ1, PQ2, and D∆. In 
particular, the nonassociation between MMSE and D∆ in 
DLB patients was markedly significant (R2= -0.185).
Dysgraphia occurs during both the earlier as well as 
the later stages during the clinical course of AD26–28 and 
is associated with attentional, motor, and memory deficits 
that develop during disorder progression.29 It has been sug-
gested to be a more sensitive indication of language deficits 
in AD than anomia.30,31 Some authors32 have observed that 
the medial walls of the cerebral hemispheres, notably the 
cingulate gyri, contain species-specific neuron fields that 
to date are not well known within the scientific community 
and yet have been implicated as the underlying cause of such 
varying conditions as dysgraphia and autism in children and 
obsessive compulsive disorder and AD in adults.33 
Table 5 Pearson product moment correlations analyses between 
MMSE, debut (years), PQ1, XF, PQ2, and D∆ in the 30 AD patients 
and 26 DlB patients
AD patients DLB patients
MMSE – PQ1 0.791 0.649
MMse – XF 0.790 0.601
MMSE – PQ2 0.788 0.705
MMse – D∆ 0.665 -0.185
Debut (years) – PQ1 -0.632 0.382
Debut (years) – XF -0.584 0.288
Debut (years) – PQ2 -0.604 0.169
Debut (years) – D∆ -0.554 0.037
Note: Debut is defined as number of years elapsed since first indication of disorder.
Abbreviations: AD, Alzheimer’s disease; D∆, difference between the measures of 
PQ1 and PQ2; DLB, dementia Lewy bodies; MMSE, Mini-Mental State Examination; 
PQ1, initial cognition test; PQ2, repeated cognition test; XF, number of complete 
sentences/minutes reached for each patient.
In a sample of 52 Japanese patients presenting mild AD 
and 22 healthy controls, writing ability composed of Kana 
writing-to-dictation and copying Kanji or dictational Kanji 
and regional cerebral blood flow using single-photon emission 
computed tomography were studied.34 Hayashi et al observed 
that while Kana writing-to-dictation and copying Kanji were 
preserved in these AD patients, writing to dictated Kanji words 
was impaired. The impaired writing of dictated Kanji words 
was associated with dysfunctional cortical activity, predomi-
nantly in the left frontal, parietal, and temporal brain regions, 
consistent with other Japanese dysgraphia studies.35,36 
 Furthermore, clear differences between AD patients and 
healthy control individuals have been found for visuomotor 
task measures, demonstrating large effect size deficits by AD 
patients, especially with visuomotor task progression through 
its varying conditions.37,38 They have observed dysgraphia, 
primarily dysexecutive agraphia, in patients with frontotem-
poral dementia and parkinsonism linked to chromosome 17. 
Patients presenting dysexecutive agraphia show not only 
difficulties in maintaining the effort inherent to writing 
but appear to lack the ability to organize their thoughts for 
expression in written text. They seem to be lacking in the 
complicated functions underlying writing that encompass 
narrative coherence, selective attention, planning, etc that 
are disturbed in executive function impairments.
The present observations of dysgraphia associated with 
deficits in semantic memory that were exacerbated acutely 
by the writing task appear to fit current notions pertaining 
to the progressive performance impairments of AD patients 
within language and cognition domains from a staging 
perspective.39
The possible relationships between dysgraphia and the 
motor functioning domain in AD has provided novel insights 
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Figure 2 examples of cognitive impairment: AD patient scores for  PQ1 (before writing) and  PQ2 (after writing).
Abbreviations: AD, Alzheimer’s disease; PQ1, initial cognition test; PQ2, repeated cognition test.
into the cognitive nature of the disorder,40 through which 
mild to moderate stage AD patients (n=59) and healthy 
elderly controls were tested over an extensive assessment of 
both the central and peripheral components of writing; the 
former performed less effectively than controls over a broad 
spectrum of writing measures. Although a predominantly 
lexical disorder was observed, there were multiple indica-
tions of associated disorders located at different stages in 
the writing/spelling system (eg, phonological route, graphe-
mic buffer, allographic store, graphic motor patterns). The 
authors concluded that there exists heterogeneous profiles 
of dysgraphia with primary signs of writing impairment in 
AD originating from changes at different points in the brain 
networks that subserve writing and spelling performance.40 
In this regard, the possibility of related motor deficits in 
dysgraphia ought to be considered since there is evidence 
for altered parietal-motor connections in AD.41 It has been 
found too that sensory-motor plasticity is impaired in the 
motor cortex of AD at an early stage of the disease.42 
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Figure 3 examples of cognitive impairment: DlB patient scores for  PQ1 (before 
writing) and  PQ2 (after writing).
Abbreviations: DlB, dementia lewy bodies; PQ1, initial cognition test; PQ2, 
repeated cognition test.
Several have indicated that agraphia is related to severity 
of AD disorder.17,43,44 Hughes et al26 have demonstrated the 
relationships between extent of MMSE impairment and pat-
terns of agraphia in AD. MMSE deficits in AD are linked 
to several comorbidity domains, including cardiovascu-
lar, ear, nose and throat, genitourinary, musculoskeletal/ 
integument, and neurologic.
We are not aware of studies that have examined the relation-
ship between cognition and dysgraphia in DLB patients, nor 
of studies that have compared the cognitive impairment after 
writing between AD and DLB. Much of the current knowledge 
regarding the relationship between DLB and AD dementia 
and cognition is derived from clinical–pathological studies of 
atypical cases of dementia and specialty clinic samples.45,46 For 
instance clinic-based studies have shown that cortical Lewy body 
pathology is associated with more rapid decline in cognition;7,47 
however, this has not been noted in all studies.48,49 
Cognitive fluctuations that occur in patients cannot be 
caused by sudden loss or gain of nerve cells;50 recent evidence 
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Figure 4 The difference (D∆) between cognitive performance in PQ1 and PQ2 by 
AD patients and DlB patients expressed as D∆ means summated over all 10 days 
of testing.
Note: Values expressed as mean AD  DlB.
Abbreviations: AD, Alzheimer’s disease; DlB, dementia lewy bodies; PQ1, initial 
cognition test; PQ2, repeated cognition test.
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Figure 5 The amount of time spent writing clearly by AD patients and DlB patients 
expressed as means in the graphia test summated over all 12 days of testing.
Note: Values expressed as mean DlB  AD.
Abbreviations: AD, Alzheimer’s disease; DlB, dementia lewy bodies.
suggests that variations in the activity of neural networks, and 
the neural plasticity is mediated by morphological and func-
tional modification of synapses, a process that depends on both 
synthesis and degradation of proteins,51 events targeting a vari-
ety of molecules in pre- and postsynaptic compartments.52 
This study, by analyzing relationships between initial 
cognitive performance (PQ1), the deterioration in cognitive 
performance following a letter-writing task (PQ1 – PQ2 = D∆), 
and dysgraphia in AD and DLB patients, suggests that cog-
nitive fluctuations that occur in patients with AD during the 
performance of handwritten scripts are not present in patients 
with DLB. During the observation period, the DLB patients 
have fluctuating confusion, inattention that is independent 
from the fatigue of the writing task.
May the differences noted in AD and DLB patients be 
due to the different speed at which the process of the protein 
degradation occurs? Is it the recovery of cognition in AD and 
DLB patients allowed to the influence of protein degradation 
in relation to temporal dynamics in other regions of the brain? 
The current study has a limitation: cognitive fluctuation was 
measured on majority of change in orientation, not other 
cognitive domains, approximately 20 minutes apart.
Conclusion
Our results can provide new insights into the mechanism of 
cognitive decline in AD and DLB patients and may be useful 
to develop a method based on dysgraphia in order to differ-
entiate the diagnosis of both types of dementia. In particular, 
the writing, in association with the cognitive questionnaire, 
can be used as part of neuropsychological tests to diagnose 
the difference between AD and DLB.
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